Nuvalent Stock (NASDAQ:NUVL)


ForecastOwnershipFinancialsChart

Previous Close

$89.22

52W Range

$55.33 - $113.51

50D Avg

$95.89

200D Avg

$80.69

Market Cap

$6.25B

Avg Vol (3M)

$515.12K

Beta

1.29

Div Yield

-

NUVL Company Profile


Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

115

IPO Date

Jul 29, 2021

Website

NUVL Performance


NUVL Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income$-149.49M$-86.11M$-45.82M
Net Income$-126.22M$-73.35M$-46.34M
EBITDA$-149.49M$-86.11M$-45.82M
Basic EPS-$-1.48$-2.13
Diluted EPS-$-1.48$-2.13

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
DICEDICE Therapeutics, Inc.
CGEMCullinan Oncology, Inc.
KNSAKiniksa Pharmaceuticals, Ltd.
VRDNViridian Therapeutics, Inc.
VTYXVentyx Biosciences, Inc.
CERECerevel Therapeutics Holdings, Inc.
TVTXTravere Therapeutics, Inc.
REPLReplimune Group, Inc.
ASNDAscendis Pharma A/S
ACLXArcellx, Inc.
GPCRStructure Therapeutics Inc.
PCVXVaxcyte, Inc.
UTHRUnited Therapeutics Corporation